Key View

• Yearly results at the upper end of guidance highlight a strong company performance throughout the year.
• Medtronic reported strong organic growth across most its segments, with the Diabetes Group expected to recover from the next quarter.
• Emerging markets' outperformance is likely to continue driven by growth in China and a number of

Key View:

• Significant disruption to medicine supply chains in the event of a ‘no-deal’ Brexit would create challenges for Irish drugmakers.
• Exacerbation of medicine shortages would further dampen the outlook for Ireland’s pharmaceutical market.
• Announcement of a 24 medicine “watch list” could pave the way for further ‘no-deal’ Brexit

Key View:

• Despite an increase to overall healthcare spending in Ireland’s 2019 budget, drugmakers will face a stagnant budget for innovative medicines.
• The government's ten-year healthcare reform plan aims to reduce operational waste on pharmaceuticals, which will exacerbate pricing pressures for drugmakers.
• Restrictive medicine reimbursement

Key View

• Perrigo's net sales have continued to decline, and with efforts to divest the Prescription Pharmaceuticals business underway, sales are likely to continue to fall in the coming quarters.
• Whilst sales for Perrigo's Consumer Healthcare Americas segment, the firm's largest, have been stable, the Consumer Healthcare International segment

Key View

• The UK's exit from the EU will present the Irish medtech industry with an opportunity to consolidate its position as a global medtech hub and a gateway to the European market.
• At the same time, Brexit will also pose a number of threats to the supply chain, the regulatory environment and foreign direct investment.
• As the UK's closest